Company profile
XBiotech Inc.
NASDAQ: XBIT · Healthcare · Biotechnology
#1166 of 1,422 Healthcare companies by revenuebottom-decile growth
EA Score
47DFH 61DQ 35GM 25SS 57
v0.1 · 65/100 weight · provisional
↑ balance-sheet leverage, Altman-Z · ↓ revenue growth (YoY), 3-yr revenue growth
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$45.5M
Employees
85
as of 2026-08-19
Market cap
$69.2M
as of 2026-08-19
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02023
Net income-$45.5M-$45.5M2025
Operating income-$55.7M-$55.7M2025
Total assets$150.1M$150.1M2025
Liabilities$9.7M$9.7M2025
Equity$140.3M$140.3M2025
Revenue trend
FY2020 – FY2023 · USD
FY20
FY20
FY20
FY21
FY22
FY23
Revenue by segment
Filed disclosures · FY2022
By product
Manufacturing Revenue100%
Clinical Trial Service Revenue0%
By geography
Not disclosed.
The read
What is XBiotech Inc.’s revenue?
XBiotech Inc. booked $0 in FY2023 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
vTv Therapeutics Inc.57CAnnovis Bio, Inc.32DPliant Therapeutics, Inc.48DEloxx Pharmaceuticals, Inc.29DEdesa Biotech, Inc.47DArch Biopartners Inc.13DNeighbors
Travis →Key facts
CEOSushma Shivaswamy
SectorHealthcare
IndustryBiotechnology
HeadquartersAustin, TX
ExchangeNASDAQ: XBIT
Employees85
IPO date2015-04-15
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.